May 28 2025
Hokkaido University to Participate in BIO International Convention 2025
Hokkaido University will be participating in the BIO International Convention 2025, to be held in Boston, Massachusetts, USA in June 2025. This global event brings together leaders from biotechnology, pharmaceuticals, academia, and finance for networking, partnering,
and showcasing cutting-edge innovations.
Researchers at Hokkaido University has been developing original and practical assets in a wide range of fields including drug discovery, diagnostic technologies,regenerative medicine, and biomaterials. At the venue, we are pleased to share the details about these programs and to explore opportunities for joint research and technology transfer. If you are interested in any of the assets listed in our portfolio, feel free to reach out to us via the BIO partnering system.
We look forward to connecting with you!
Assets Hokkaido University(BIO International 2025)
① Drug Delivery & Nucleic Acid Therapeutics
No.1: A Novel Lipid for Hepatic stellate cells (HSC)
No.2: Optimized LNP for the spleen delivery
No.3: Novel Helper Lipids that accelerate endosomal escapes
No.4: Lipid nanoparticles for ribonucleoprotein delivery for in vivo genome editing
No.5: Novel Delivery programs for NK cells for cancer treatment
No.13: Programmable “srRNA” therapeutics
No.14: Gene therapy for mitochondrial diseases using genome editing
②Neurology, Regeneration & Rare Diseases
No.6: A neutrophil NETs inhibitor for axon regeneration
No.7: Therapeutic Protein for Promotion of Axon Regeneration in PNS and CNS
No.8: A new therapeutic peptides for Alzheimer’s disease
No.9: Novel suppressors of TDP aggregation for ALS and FTLD
③Oncology & Immunotherapy
No.15: Novel Technology to Improve T-cell Quality for CAR-T and T-cell-Based Therapies
No.17: STAP-1 Therapeutic Peptide for Autoimmune disease
No.18: Pancreatic cancer treatment drugs
No.19: Novel STING Agonist
No.20: Pancreatic cancer therapeutic peptide
No.22: Intracellular delivery of anti-interleukin-6 antibodies using PIECE
No.23: A novel monoclonal antibody for ATL and Burkitt lymphoma
No.24: Treatment resistance reducing agent for treatment-resistant cancer
④Infectious, Respiratory & Veterinary Medicine
No.16: Interstitial pneumonia treatment equipment
No.25: Novel Antibodies for Marburg Virus Therapy
No.26: A Highly Cross-Neutralizing Antibody for Ebolavirus Therapy
No.27: A broad-spectrum antiviral nucleoside analog
No.28: Anti-PD-L1 antibody (veterinary medicine)
No.30: Combination therapy of anti-PD-L1 or anti-PD-1 antibody and radiation therapy
⑤Diagnostics & Evaluation Tools
No.35: Development of blood fibrosis markers for nonalcoholic steatohepatitis
No.36: Comprehensive detection method for parasites using portable NGS
No.37: Methods and kits for detecting human a-defensin HD5
No.38: Method for Temporal Evaluation of Reproductive Toxicity Using Bioluminescent Imaging
⑥Drug Discovery Platforms & Peptide Technologies
No.10: Novel peptides for glaucoma treatment
No.11: Anti-photoaging topical agent
No.12: A repurposing drug candidate for rebound bone resorption in osteoporosis
No.32: Peptide optimization strategy
No.33: Peptide Scanning Method Using Hydrazide Amino Acids
No.34: New macrocyclic peptide library and peptide engineering technologies
No.39: Photoswitchable Auxin-Inducible Degron System
■URL
